Stryker

SYK · NYSE

$304.40+$6.46 (+2.17%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $297.94

SYK analyst rating

BuyConsensus of 22 analysts over the last 12 months. 77% rate it a buy.

Strong buy0
Buy17
Hold5
Underperform0
Sell0

12-month price target · 28 analysts

Average $377.13 (+23.9% upside)

Low: $300.98
Now: $304.40
High: $488.25

Upgrades and downgrades

The latest rating actions, newest first

SYK analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
BTIG	Oct 12, 2026	Maintains	Buy	$358.00 → $316.00	48%
Truist Securities	Oct 7, 2026	Maintains	Hold	$340.00 → $310.00	50%
Barclays	Oct 7, 2026	Initiates	Overweight	$375.00	68%
Stifel	Sep 30, 2026	Maintains	Buy	$360.00 → $330.00	62%
TD Cowen	Sep 22, 2026	Maintains	Hold	$355.00 → $298.00	61%
Canaccord Genuity	Sep 18, 2026	Maintains	Buy	$400.00 → $385.00	51%
Citigroup	Sep 10, 2026	Maintains	Buy	$399.00 → $360.00	60%
Wells Fargo	Sep 9, 2026	Maintains	Overweight	$418.00 → $348.00	54%
Wolfe Research	Aug 13, 2026	Downgrade	Outperform → Peer Perform	—	45%
Citizens	Aug 3, 2026	Maintains	Market Outperform	$440.00 → $400.00	42%

The case for and against

Updated Oct 14, 2026

Bull case

Stryker is viewed as a core MedTech holding with a durable moat, supported by category leadership in orthopedic robotics, operating room equipment, and a broad portfolio that has consistently gained share across higher-growth end markets. The company is expected to deliver high-end MedTech sales growth, 30 bps-plus operating margin expansion, double-digit EPS growth, and strong free cash flow, while FY26 organic sales guidance of 8.0%-9.5% and adjusted diluted EPS of $14.90-$15.10 underscore resilient fundamentals despite a cyberattack-related 1Q disruption. Its ability to outpace underlying orthopedic market growth by 200-300 bps in FY26, backed by new product launches, rising implant utilization, international expansion, and ongoing M&A, supports a positive long-term outlook.

Bear case

Stryker is facing a softer near-term fundamental setup as seasonal slowdowns in elective procedures, persistent Peripheral Vascular supply constraints, and Europe-driven Joint Replacement weakness are pressuring 3Q26 performance and dragging 2026 organic revenue growth to 8.3%, the low end of guidance. Management’s inability to quantify the impact, combined with a cyberattack that materially hit 1Q26, creates execution risk around FY26 EPS of $14.96 near the bottom of the $14.95-$15.10 range, while continued softness in Hips and Knees is especially concerning given Europe’s outsized impact. Longer term, rising competition in orthopedic robotics, slower adoption in the ASC setting, and uncertainty around M&A conversion weaken confidence in Stryker’s ability to sustain premium growth and defend margins.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.